新加坡的Restalyst开发新的方法改善肝癌诊断

StephenW

                                        Singapore's Restalyst develops new method to improve liver cancer diagnosis               
       
                                                                                                                                                       
                                               
                                                                                PRESS RELEASE PR Newswire
                       
                        Nov. 9, 2017, 03:00 AM                                       
               
       
                        SINGAPORE, Nov. 9, 2017 /PRNewswire/ -- Singapore biomedical firm Restalyst has developed a new algorithm to detect liver cancer more accurately, improving the sensitivity to 90%. The new methodology looks at three factors: membrane bound protein ERBB3, AFP (alpha fetoprotein) and age of patient. It will detect and identify liver cancer more effectively, and better distinguish liver cancer from chronic hepatitis condition.
An AFP test is commonly used to detect and diagnose cancers of the liver, as it's relatively inexpensive, simple to perform and widely available. Because of AFP low sensitivity, up to six hepatocellular carcinoma (HCC) positive patients may not be detected using AFP alone at cut-off 20ng/ml. In some cases, patients with chronic liver disease, especially those with a high degree of hepatocyte regeneration (e.g. hepatitis C virus), can have high levels of AFP -- even in the absence of cancer. But it may not correctly identify and distinguish patients with the disease from those without.
The new algorithm was jointly developed by Restalyst and Chang Gung Memorial Hospital based on a patented technology by Professor Hsieh Sen Yung from Chang Gung Memorial Hospital in Taiwan. It's able to better identify liver cancer as compared to using AFP alone and has received CE-IVD Mark, the requirements of the in vitro diagnostic Medical Device Directive in the European Union.
Restalyst will launch the use of the algorithm at MEDICA 2017, a global forum for medical technology, on November 13-16 in Dusseldorf, Germany, Hall 3 Booth 74, as part of the Singapore Pavilion.
HCC is the most common form of liver cancer and causes up to one million deaths globally every year. Each year, approximately half a million people worldwide are newly diagnosed with HCC. HCC occurs most often in people with chronic liver diseases, such as cirrhosis caused by hepatitis B or hepatitis C infection or exposure to toxins such as alcohol or aflatoxin.
If caught early, HCC can be cured with surgery or transplant. In more advanced cases when it cannot be cured, treatment and support can help patients live longer and better. Patients with HCC have a low survival rate (5-year survival less than 5 per cent). Those in the early stage who receive potentially curative therapy, such as liver transplant, surgical resection, or ablation, have better prognosis (5-year survival ranges between 40-70 per cent).
Ivan Lim
+65-6543-3640
rel="nofollow">[email protected]

StephenW

新加坡的Restalyst开发新的方法改善肝癌诊断
新闻发布PR Newswire
2017年11月9日，上午03:00

新加坡，2017年11月9日/新华美通/ - 新加坡生物医药公司Restalyst开发了一种新的算法来更精确地检测肝癌，将敏感度提高到90％。新的方法学考虑三个因素：膜结合蛋白ERBB3，AFP（甲胎蛋白）和患者年龄。它将更有效地检测和鉴别肝癌，更好地区分肝癌和慢性肝炎。

AFP测试通常用于检测和诊断肝癌，因为它相对便宜，操作简单且广泛可用。由于AFP灵敏度低，在截止20ng / ml时单独使用AFP可能检测不到6个肝细胞癌（HCC）阳性患者。在某些情况下，慢性肝病患者，尤其是那些肝细胞再生程度较高的患者（如丙型肝炎病毒），即使在没有癌症的情况下，也可能具有较高水平的AFP。但可能无法正确识别和区分患者和没有患者。

新算法是由Restalyst公司和长庚医院根据台湾长庚医院的Hsieh Sen Yung教授的专利技术共同开发的。与单独使用AFP相比，它能够更好地识别肝癌，并且已经获得了CE-IVD Mark，这是欧盟体外诊断医疗设备指令的要求。

作为新加坡馆的一部分，Restalyst将于11月13日至16日在德国杜塞尔多夫3号展厅74号展位推出使用该算法的医疗技术全球论坛MEDICA 2017。

HCC是最常见的肝癌，每年在全球范围内导致多达100万人死亡。全球每年约有50万人被诊断为HCC。 HCC最常见于慢性肝病患者，如由乙型肝炎或丙型肝炎感染引起的肝硬化或暴露于毒素如酒精或黄曲霉毒素。

如果早期发现，HCC可以通过手术或移植手术治愈。在更高级的情况下，无法治愈，治疗和支持可以帮助患者寿命更长，更好。 HCC患者存活率低（5年生存率低于5％）。早期接受潜在治愈性治疗（如肝移植，手术切除或消融）的患者预后较好（5年生存率在40-70％之间）。

Ivan Lim
+ 65-6543-3640
相对= “nofollow”> [email protected]